The Readout LOUD Allison DeAngelis and Adam Feuerstein STAT Plus: Listen: Live! From the STAT Breakthrough Summit West
Pharma Andrew Joseph STAT Plus: Obesity drug from Roche succeeds in early test, sending company shares up
Pharma Isabella Cueto and Elaine Chen STAT Plus: Novo to test Wegovy and other obesity drugs against alcohol-related liver disease
Biotech Elaine Chen STAT Plus: 4 burning questions about Amgen’s obesity drug, a potential Wegovy and Zepbound competitor
The Readout LOUD Adam Feuerstein and Allison DeAngelis STAT Plus: Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama
Biotech Elaine Chen STAT Plus: Eli Lilly raises earnings guidance as it ramps up Mounjaro, Zepbound manufacturing
The Readout LOUD Allison DeAngelis and Adam Feuerstein STAT Plus: Listen: A new obesity startup, an acquisition gone wrong, & the future of Teladoc
Biotech Allison DeAngelis STAT Plus: ARCH, Medicines Co. veterans raise $290 million for in-licensed obesity drugs
Health Andrew Joseph European regulators find no evidence of link between new obesity medicines and suicidal thoughts
Pharma Elaine Chen STAT Plus: Positive trial results set up obesity drug Wegovy for use against heart failure
First Opinion Patrick Skerrett STAT readers on biotech and national security, liquid-only diets before colonoscopy, and the value of weight loss drugs
First Opinion Dana P. Goldman and Alison Sexton Ward Medicare coverage of weight loss drugs could save the U.S. billions of dollars
Health Elaine Chen Ozempic-like drugs linked to low, but increased risk of post-endoscopy pneumonia, study finds
First Opinion Lisa Shah Oprah kicked off a national conversation on obesity and GLP-1 drugs. Let’s have it
Biotech Andrew Joseph STAT Plus: Viking Therapeutics to move its oral obesity drug into Phase 2 study after early success
Pharma Andrew Joseph STAT Plus: Novo Nordisk to acquire heart disease-focused Cardior Pharmaceuticals in deal worth $1.1 billion
Health Elaine Chen STAT Plus: Despite new Wegovy coverage, Medicare patients may face high drug costs and other hurdles
Politics John Wilkerson STAT Plus: Medicare expected to negotiate obesity drug prices soon, new analysis predicts
Insurance Rachel Cohrs Zhang STAT Plus: Medicare couldn’t cover Wegovy for weight loss. But now that it’s also a heart drug, the door is open
Biotech Adam Feuerstein STAT Plus: First medicine developed to treat MASH expected to be approved soon